BlackRock’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-34,356
| Closed | -$75K | – | 6047 |
|
|
2022
Q2 | $75K | Buy |
34,356
+7,624
| +29% | +$15.2K | ﹤0.01% | 5317 |
|
|
2022
Q1 | $50K | Sell |
26,732
-1,260
| -5% | -$2.29K | ﹤0.01% | 5416 |
|
|
2021
Q4 | $61K | Buy |
27,992
+1,373
| +5% | +$3.71K | ﹤0.01% | 5376 |
|
|
2021
Q3 | $89K | Sell |
26,619
-6,144
| -19% | -$16.7K | ﹤0.01% | 5169 |
|
|
2021
Q2 | $88K | Buy |
32,763
+26,336
| +410% | +$59.5K | ﹤0.01% | 5089 |
|
|
2021
Q1 | $14K | Sell |
6,427
-3,433
| -35% | -$9.76K | ﹤0.01% | 5063 |
|
|
2020
Q4 | $24K | Buy |
9,860
+1,755
| +22% | +$3.45K | ﹤0.01% | 4768 |
|
|
2020
Q3 | $17K | Sell |
8,105
-3,402
| -30% | -$9.71K | ﹤0.01% | 4745 |
|
|
2020
Q2 | $34K | Sell |
11,507
-3,346
| -23% | -$9.15K | ﹤0.01% | 4626 |
|
|
2020
Q1 | $39K | Sell |
14,853
-738
| -5% | -$3.33K | ﹤0.01% | 4524 |
|
|
2019
Q4 | $77K | Sell |
15,591
-164
| -1% | -$888 | ﹤0.01% | 4480 |
|
|
2019
Q3 | $94K | Sell |
15,755
-902
| -5% | -$6.05K | ﹤0.01% | 4452 |
|
|
2019
Q2 | $108K | Buy |
16,657
+3,784
| +29% | +$24.3K | ﹤0.01% | 4461 |
|
|
2019
Q1 | $87K | Sell |
12,873
-882
| -6% | -$5.28K | ﹤0.01% | 4395 |
|
|
2018
Q4 | $56K | Buy |
+13,755
| New | +$90.6K | ﹤0.01% | 4460 |
|
BlackRock's ETTX Position: Q3 2022 in Review
BlackRock sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 34,356 shares — an estimated $75K sold.
BlackRock first reported a position in ETTX in Q4 2018 and held it in 15 quarters. The position peaked at $108K in Q2 2019. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.
- BlackRock reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
- BlackRock sold 34,356 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $75K.
- BlackRock first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2018 and held it in 15 quarters.
- BlackRock's Entasis Therapeutics Holdings Inc. position peaked at $108K in Q2 2019.
- 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.
Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.